Phase I Study of Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 11 Jul 2017
At a glance
- Drugs M 6620 (Primary) ; Veliparib (Primary) ; Cisplatin
- Indications Solid tumours
- Focus Adverse reactions
- 06 Jul 2017 Planned primary completion date changed from 30 Jun 2017 to 31 Dec 2017.
- 02 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 12 Apr 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.